Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) is possibly approaching a major achievement in its business, so we would...
Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.